This study was conducted in accordance with the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) 15 statement and the Preferred Reporting Items for Systematic Reviews and Background and Purpose-The ankle-brachial index (ABI) is a fast, cheap, noninvasive indicator of atherosclerotic burden that may also be a predictor of stroke recurrence. In this systematic review and meta-analysis, we sought to explore ABI's merit as a marker for stroke recurrence and vascular risk by synthesizing the data currently available in stroke literature. Methods-We searched Embase, MEDLINE, and Pubmed databases for prospective cohort studies that included consecutive patients with stroke and transient ischemic attack, measured ABI at baseline, and performed a follow-up assessment at least 12 months after initial stroke or transient ischemic attack. The following end points were chosen for our analysis: recurrent stroke and combined vascular end point (recurrent vascular event or vascular death). Crude risk ratios and adjusted Cox proportional hazard ratios were combined separately using the random-effects model. Study-level characteristics (eg, percent of cohort with a history of hypertension, average cohort age, level of adjustment, and mean follow-up duration) were included as covariates in a metaregression analysis. Results-We identified 11 studies (5374 patients) that were not significantly heterogeneous. Pooling adjusted hazard ratios showed that low ABI was associated with both an increased hazard of recurrent stroke (hazard ratio, 1.70; 95% confidence interval, 1.10-2.64) and an increased risk of vascular events or vascular death (hazard ratio, 2.22; 95% confidence interval, 1.67-2.97). Conclusion-Our results confirm the positive association between ABI and stroke recurrence. Further studies are needed to see whether inclusion of ABI will help improve the accuracy of prediction models and management of stroke patients.
A ccurate prediction models for stroke recurrence are essential for stroke management. In the first year after ischemic stroke, cumulative risks range from 7.0% to 20.6%. 1 The risk of recurrence is especially high in the first few months after the index event, at ≈3.1% in the first 30 days. 1 For patients with incident transient ischemic attack (TIA), the risk of stroke is as high as 3.5% to 9.9% in the first 48 hours. 2 Despite the elevated risk of recurrence, high-performance risk prediction models remain elusive.
The ankle-brachial index (ABI), defined as the ratio between systolic blood pressures measured at the ankle and arm of a patient in the supine position, has been shown to be an efficient method for detecting arterial stenosis in the lower extremities (specificity: 83.3%-99.0% and sensitivity: 15.0%-79.0%, using ABI≤0.9 as a cutoff value). 3 It is currently used to screen for peripheral artery disease (PAD).
In addition, recent studies show that decreased ABI associates with both cardiovascular events and higher rates of cardiovascular morbidity and mortality, independent of the Framingham Risk Score. [4] [5] [6] [7] [8] [9] However, it remains unclear whether ABI is a useful tool for assessing recurrent stroke risk. Some studies have shown that decreased ABI is associated with increased recurrent stroke risk, [10] [11] [12] whereas others have not. 13, 14 We, therefore, conducted a systematic review and metaanalysis to determine whether decreased ABI associates with increased recurrent stroke risk.
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Meta-Analyses (PRISMA) 16 recommendations for reporting. To identify relevant articles, we searched PubMed, Medline, and EMBASE databases between 1975 and April 2015 using a combination of the following search terms, both as subject headings or as plain text: ankle-brachial index (synonyms: ankle brachial pressure index, ankle arm index, and ABI), cerebrovascular disorders, cerebrovascular accident, stroke, brain ischemia, and brain infarction (for complete listing of search terms according to electronic database, see Methods in the online-only Data Supplement). T.G.L. and J.B.H. independently screened titles, abstracts, and full-text articles for relevance according to inclusion/exclusion criteria (inclusion/exclusion criteria are given below). There were no discrepancies in the selection of studies between the 2 raters. References of selected articles and relevant reviews were hand searched to identify further relevant articles.
Inclusion/Exclusion Criteria
Human prospective cohort studies that included participants aged >18 years who had provided informed consent were eligible for inclusion if they included patients with acute ischemic stroke or TIA, assessed ABI with a Doppler probe at baseline, performed follow-up cerebrovascular event assessment for at least 12 months after initial stroke or TIA, and assessed the association between ABI and at least 1 of the following end points: recurrent stroke, vascular event, or vascular death. Studies were excluded if cohorts were comprised of a more specific, high-risk stroke subpopulation (eg, patients with atrial fibrillation, chronic kidney, disease, or diabetes mellitus). When articles had overlapping cohorts, the most recent publication (ie, thought to have the longest follow-up and highest precision) was included.
Data Extraction
We extracted cohort characteristics (cohort size, mean age, percentage of male patients, percentage of patients with a history of hypertension, mean ABI, average follow-up duration, year of publication, and inclusion and exclusion criteria of cohort), ABI cutoff, ABI measurement protocol, outcomes used for analysis, covariates used in multivariate models, and mean follow-up duration from all eligible studies. We additionally extracted adjusted Cox regression hazard ratios (HRs) and their corresponding confidence intervals (CIs) from studies that performed survival analyses. Event counts during followup (either recurrent stroke or any vascular event or death) for the normal and low-ABI groups were used to calculate a crude risk ratio (RR). The HRs and event counts that were extracted were based on the 0.9 cutoff value in all studies except 1 that reported data based on a cutoff value of 0.8.
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Statistics
The following end points were chosen for our analyses: recurrent stroke and combined vascular end point (recurrent vascular event/vascular death). Crude risks ratios corresponding to the 2 end points from each study were pooled using the random-effects model. A second random-effects meta-analysis (inverse variance weighted method) was performed by pooling adjusted HRs corresponding to the 2 end points. Log-transformed CIs were used to obtain SEs of the HR. For all meta-analyses, heterogeneity was assessed using I 2 and Q statistics. Heterogeneity was considered significant if the P value for Cochrane Q was ≤0.05 and was classified as low (I 2 values, 0%-25%), moderate (I 2 values, 25%-50%), or high (I 2 ≥75%).
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To investigate whether variance among effect sizes could be explained by study-level characteristics, we performed a randomeffects metaregression and subgroup analyses. For the metaregression, the most adjusted effect measure from each study was used, and the following study-level characteristics were modeled as covariates among the studies that reported them: age, hypertension, level of adjustment, and duration of follow-up. The level of adjustment was rated with a score of 0, 1, or 2 (0=no adjustment, 1=adjust-ment with at least age or 1 vascular risk factor, and 2=adjustment with age and at least 2 vascular risk factors). Subgroup analyses with crude RRs were conducted, comparing studies including or excluding stroke patients with cardioembolic cause, studies with 1 year versus more than a year of follow-up, and studies that did or did not include PAD-related events in the definition of the composite vascular end point.
A leave-one-out sensitivity analysis was performed by repeating the meta-analysis, each time with 1 of the included studies omitted, to see whether any one study had a disproportionately large influence on the pooled relative risk. Finally, the likelihood of publication bias was explored using a funnel plot and Harbord modified test for small-study effects that has lower false-positive rates than the original Egger test.
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Results
Search Results
Combining search results from the PubMed, MEDLINE, and Embase databases yielded 1317 titles and abstracts for initial screening. Figure 1 shows a flow diagram outlining the search and inclusion process. Of the 20 potentially relevant studies, 9 studies were excluded after review of the abstract. One study 19 was excluded because of a short follow-up time (30 days) and one 14 because it did not examine the outcome of interest. Two studies 20, 21 were excluded because they did not examine the relationship between low ABI and recurrence of vascular events, and 4 additional studies [22] [23] [24] [25] were excluded because they leveraged data from general population-based cohorts. Finally, there was 1 study that did not use a Doppler probe for ABI measurement. 26 Therefore, 11 original, nonoverlapping studies, [10] [11] [12] [13] [27] [28] [29] [30] [31] [32] [33] with a total of 5374 patients, met the inclusion criteria and had data extracted for the meta-analysis. Table I in the online-only Data Supplement summarizes the characteristics of the studies included in the meta-analysis. Included cohorts consisted of patients with ischemic stroke or TIA, although there were several unique inclusion and exclusion criteria for patient recruitment. Five studies 12, 27, 28, 30, 32 excluded patients with cardioembolic stroke, and 1 study 10 excluded patients who exhibited symptomatic peripheral arterial disease. Patients with TIA were excluded in 1 study. 13 One study included only patients with modified Rankin Scale score of ≤1 and patients aged <80 years. 30 One study included both patients with stroke and TIA, if imaging studies showed evidence of intracranial atherosclerotic disease. 12 Mean followup times ranged from 12 to 37 months.
Methodological Comparisons of Studies Included in the Meta-Analysis
ABI measurement protocols varied slightly across the studies. All of the included studies used a Doppler probe to assess systolic blood pressures. In general, the maximum systolic pressure of either the posterior tibial artery or the anterior tibial artery (or the dorsalis pedis artery) was used for calculation. Systolic pressures from the brachial artery were either averaged or the maximum value was used. In some studies, ABI was calculated separately for the left and right extremities and the lower value was considered for analysis. If left and right brachial artery pressures differed by >10 mm Hg, the higher value was used for ABI calculation (Table II in studies reported stroke recurrence counts for low and normal ABI groups. Stroke recurrence included ischemic stroke in all 9 studies, and in 2 studies, 13, 28 hemorrhagic strokes were also counted as stroke recurrence.
All of the studies reported an effect measure based on a primary end point of composite vascular events, with small differences in its definition. All included studies except one 33 combine stroke recurrence, myocardial infarction, or vascular death as components of the combined vascular end point. New onset symptomatic peripheral arterial disease was included in 4 studies. 11, 28, 30, 32 Death from causes other than vascular events was included in 3 studies. 27, 29, 32 The risks of combined vascular events and stroke recurrence per year of follow-up ranged from 7.1% to 33.3% and 3.1% to 21.4% for the low-ABI group and from 3.8% to 14.1% and 3.1% to 9.7% for the normal ABI group, respectively (Table III in 
Meta-Analysis of Crude Relative Risks
Event counts for recurrent stroke were available in 9 studies (4712 patients, all studies except 2 30, 32 ). For the combined vascular end point, event counts were available in all included studies (5374 patients). Low heterogeneity was observed among the crude RRs (recurrent stroke: I 2 =0.0% and combined vascular end point: I 2 =12.7%). Pooling of relative risks for recurrent stroke resulted in an overall RR of 1.55 (95% CI, 1.28-1.88; Figure 2A ). Pooling of relative risks for the combined vascular end point yielded an overall RR of 1.91 (95% CI, 1.65-2.22; Figure 2B ).
Meta-Analyses of Time to Event Analyses
Four studies (1780 patients) 10, 11, 13, 28 assessed the relationship between ABI and stroke recurrence, and 6 studies (2003 patients) 10, 11, 13, [28] [29] [30] assessed the relationship between ABI and combined vascular end point, both using multivariate Cox regression with age and at least 1 vascular risk factor as covariates. Moderate heterogeneity was observed for both end points (recurrent stroke: I 2 =31.4% and combined vascular end point: I 2 =27.8%). The pooled HR for stroke recurrence was 1.70 (95% CI, 1.10-2.64; Figure 3A ). For the combined vascular end point, the pooled HR was 2.22 (95% CI, 1.67-2.94; Figure 3B ).
Meta-Regression and Subgroup Analysis
Univariate and multivariate meta-regression was performed using the most adjusted effect sizes from all studies for the combined vascular end point to estimate the extent of confounding present in crude RRs. As Table IV in the online-only Data Supplement shows, no significant associations were observed, both in univariate and multivariate models. Only a small portion (τ 2 =0.035, adjusted R-squared=0 in the multivariate model) of the between-studies variance could be explained by the chosen study-level characteristics. Stratification of our data (ie, cardioembolic stroke included yes or no, follow-up of 1 year versus >1 year) did not result in the reduction of summed heterogeneity. However, when studies that included events related to PAD in the vascular end point and those that did not were analyzed separately, heterogeneity as measured by I 2 was estimated to be 0.0% for both subgroups ( Figure I in the online-only Data Supplement). 
Sensitivity Analysis and Publication Bias
When the meta-analysis was repeated with 1 study removed, for each of the studies included in the overall analysis, the pooled RR for the combined vascular end point ranged from 1.82 to 2.02 and for stroke recurrence, from 1.50 to 1.66 ( Figure  II in the online-only Data Supplement). Thus, the effect of any one study on the overall summary estimate remained low. Potential publication bias was explored visually using a funnel plot (Figure 4 ), and formally with Harbord test, using unadjusted odds ratios for combined vascular events (heterogeneity was low; τ 2 =0.0078). The intercept was 1.66, and the P value was 0.094, indicating slight evidence for publication bias.
Discussion
A systematic search for studies investigating the relationship between low ABI and recurrent stroke risk, and subsequent quantitative synthesis of reported effect measures, suggests that low ABI is an independent risk factor for both stroke recurrence and further vascular events.
Two previous meta-analyses that investigated the relationship between low ABI and stroke risk in stroke-free cohorts performed additional analyses on recurrent stroke. Sander et al 34 combined 4 relevant studies (2762 patients) and obtained a pooled HR of 2.1 (95% CI, 1.6-2.8) for recurrent stroke in acute stroke patients with low ABI. Fan et al 35 combined
RRs from 3 studies with short-and long-term follow-ups (593 patients) and obtained a pooled RR of 3.02 (95% CI, 1.26-7.08) for recurrent stroke in stroke patients with low ABI. Our study likely yielded more conservative HR estimates, as we pooled data from a larger overall sample size and larger sample sizes frequently correspond to lower risk estimates. 36 In addition, the lower unadjusted RRs can be explained by the fact that a higher rate of recurrence in the low-ABI group compared with the normal ABI group leads to a lower overall relative risk with increasing follow-up durations, as the population at risk in the low-ABI group decreases more sharply over time than in the normal ABI group. 
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Despite more conservative risk estimates than previous analyses, our data suggest that low ABI is a robust predictor of future stroke and vascular event risk. The point estimate of the adjusted HR meta-analysis is in the same direction and of similar magnitude as the crude risk estimate meta-analyses. Nonetheless, an individual patient data meta-analysis is needed to fully reduce the effect of residual confounding.
If further studies are able to show corresponding improvement in the predictive performance of available risk prediction models with the addition of ABI measurement, novel strategies to improve overall stroke outcome can be developed. Screening with ABI would identify patients with stroke at especially high absolute risk. In a recent topical review, Banerjee et al 37 reported high prevalence of multiterritory vascular disease in patients with stroke and the high effect that this has on cardiovascular risk-specifically vascular death. Various strategies to reduce recurrence risk, for example, more aggressive treatment of concurrent vascular risk factors through different medication strategies or promoting patient adherence in patients, can be targeted toward the high-risk patients identified, potentially with the help of ABI. Currently, even if PAD is detected-although there are currently no guidelines that recommend PAD screening in patients with stroke 38 -stroke patients with PAD are treated far less frequently with secondary prevention medications (eg, statins and antiplatelets) than coronary artery disease patients with PAD, indicating that there is room for such a more intensified secondary prevention strategy. 37 This study has several limitations. First, there was considerable variation in the covariates entered into multivariate models across studies, which likely explains the heterogeneity we observed in our adjusted HR meta-analysis. This makes it difficult to estimate the true effect size from survival analysis studies, as residual confounding will be present. Second, the dichotomization of ABI results in the loss of potentially useful information contained in the actual index itself. None of the included studies treated ABI as a continuous variable in their analysis, highlighting a need for further exploration. Extremely low ABI likely entails a higher rate of vascular recurrence than mildly low ABI. Moreover, the use of different thresholds for dichotomization among studies resulted in misclassification. However, when we performed the same analyses using data only from the studies that applied the 0.9 cutoff value, we obtained comparable results (pooled crude RR for stroke recurrence: 1.52 [95% CI, 1.25-1.85], combined vascular end point: 1.93 [95% CI, 1.65-2.26], and pooled adjusted HR for both outcomes unchanged). Third, our analysis, being a systematic review of prognostic studies, is at especially high risk of reaching a biased conclusion, as only published observational studies are eligible for inclusion. As expected, both the funnel plot and Harbord test revealed slight evidence for publication bias, indicating that smaller negative studies are missing, with an estimated relative risk corrected for publication bias, of 1.66 for the combined vascular end point. Fourth, follow-up times varied considerably (from 12 months to 5 years). This makes the interpretation of the pooled effect sizes problematic, as there may be variation in the effect of low ABI on the rate of recurrence over time. For example, 1 study 19 showed that low ABI is associated with especially high risk of early stroke recurrence with an adjusted HR of 9.9 (95% CI, 2.12-46.24). It is possible that longer follow-up times result in decreased effect measures, although this was not the case in our study as shown through the lack of significant correlation in the meta-regression analysis. However, the meta-regression analysis itself is of limited use because of the low number of included studies, which restricts the number of covariates we can investigate. Overall, more studies are needed for a more precise estimation of the association of ABI with recurrent stroke.
ABI is an accessible measure that has shown a consistently high level of association with increased recurrence risk in patients with stroke. Our review combined results from available studies and found a robust and consistent association of low ABI with recurrent stroke and future vascular events, independent of established vascular risk factors. Further studies are needed to determine whether including ABI in existing risk prediction models improves their predictive power and ultimately, whether interventions targeting newly identified high-risk patients are effective in reducing stroke recurrence risk. 
Sources of Funding
Disclosures
None. * β is the regression coefficient, SE is the standard error of β, P is the p-value corresponding to β and the standard error of β, and τ 2 is the residual between-studies variance in the fitted model. Random effects meta-analysis estimates, when performed with one study omitted, of crude relative risks, for the outcome of A) combined vascular endpoint and B) stroke recurrence. Circles represent the pooled relative risk, short bars delineate 95% confidence intervals. The study omitted is named on the left. Solid vertical lines indicate random effects meta-analysis estimates and 95% confidence intervals when all studies are included. 
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